C-Reactive Protein Relaxes Human Vessels In Vitro

Objective—C-reactive protein (CRP) is a sensitive marker of inflammation and a prognostic marker in cardiovascular disease. Evidence suggests direct biological activities of CRP within the vascular wall. The study was designed to examine the vasoreactive effects of CRP. Methods and Results—Human internal mammary artery rings were obtained during cardiovascular bypass surgery and suspended in an organ bath chamber. The rings were precontracted with endothelin-1, and response to cumulative concentrations of CRP was obtained. Experiments were repeated after initial incubation with 20, 40, and 60 mmol/L KCl, the potassium channel blockers BaCl, tetraethylammonium chloride, and glibenclamide, and the NO synthase inhibitor N-monomethyl-l-arginine and also after removal of the endothelium. CRP caused dose-dependent relaxation of human internal mammary artery rings, which was not affected by preincubation with N-monomethyl-l-arginine or removal of the endothelium. Maximum relaxation response to CRP (79.5±10%) was attenuated by KCl (2.5±11.5%, P <0.001), BaCl (24.5±7.5%, P <0.001), and tetraethylammonium chloride (34.9±8.25%, P <0.01) but not by glibenclamide. Conclusions–The present study demonstrates that CRP exerts an endothelium-independent vasorelaxing effect via potassium channels. Thus, the study suggests a role of CRP in the regulation of vascular tone.

[1]  V. Hombach,et al.  C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis , 2001 .

[2]  P. Ridker,et al.  Novel clinical markers of vascular wall inflammation. , 2001, Circulation research.

[3]  F. Crea,et al.  Unstable Angina and Elevated C-Reactive Protein Levels Predict Enhanced Vasoreactivity of the Culprit Lesion , 2001, Circulation.

[4]  V. Pasceri,et al.  C-reactive protein: linking inflammation to cardiovascular complications. , 2001, Circulation.

[5]  J. Volanakis,et al.  Human C-reactive protein: expression, structure, and function. , 2001, Molecular immunology.

[6]  James T. Willerson,et al.  Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001 .

[7]  V. Hombach,et al.  C-Reactive Protein–Mediated Low Density Lipoprotein Uptake by Macrophages: Implications for Atherosclerosis , 2001, Circulation.

[8]  N Rifai,et al.  High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. , 2001, Clinical chemistry.

[9]  A. Lerman,et al.  Altered effects of potassium channel modulation in the coronary circulation in experimental hypercholesterolemia. , 2001, Atherosclerosis.

[10]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[11]  W. Koenig,et al.  C-Reactive Protein in the Arterial Intima: Role of C-Reactive Protein Receptor–Dependent Monocyte Recruitment in Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[12]  S. Fichtlscherer,et al.  Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease , 2000, Circulation.

[13]  T. D. Du Clos,et al.  Function of C-reactive protein. , 2000 .

[14]  J. Connell,et al.  Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. , 2000, Clinical science.

[15]  P. Cohen,et al.  Insulin and insulin‐like growth factor‐I cause vasorelaxation in human vessels in vitro , 2000, Coronary artery disease.

[16]  T. D. Du Clos.  Function of C-reactive protein , 2000, Annals of medicine.

[17]  Aroon D. Hingorani,et al.  Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans , 1999, Circulation.

[18]  P Toutouzas,et al.  Heat production of atherosclerotic plaques and inflammation assessed by the acute phase proteins in acute coronary syndromes. , 2000, Journal of molecular and cellular cardiology.

[19]  S. Bhakdi,et al.  Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[20]  C. Visser,et al.  C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? , 1999, Circulation.

[21]  C. Mold,et al.  Regulation of complement activation by C-reactive protein. , 1999, Immunopharmacology.

[22]  W. Koenig,et al.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[23]  R. Rizza,et al.  Insulin and insulin-like growth factor-I cause coronary vasorelaxation in vitro. , 1998, Hypertension.

[24]  M. Nelson,et al.  Physiological roles and properties of potassium channels in arterial smooth muscle. , 1995, The American journal of physiology.

[25]  M. Nelson,et al.  Regulation of arterial tone by activation of calcium-dependent potassium channels. , 1992, Science.

[26]  J. Raud.  Vasodilatation and inhibition of mediator release represent two distinct mechanisms for prostaglandin modulation of acute mast cell‐dependent inflammation , 1990, British journal of pharmacology.

[27]  T. Williams,et al.  Oedema and vasodilatation in inflammation: the relevance of prostaglandins. , 1977, Postgraduate medical journal.